‘Breakthrough’ Drugs Get ‘Road-MaPP’ – Complete With Communication Timetable
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Manual of Policy and Procedures describes specific actions FDA review staff will take once a product has received “breakthrough therapy” designation, with an emphasis on more meetings, more frequently.